CRISM Therapeutics Corporation (CRTX) — Net Asset Quality Index
CRISM Therapeutics Corporation (CRTX) has a Net Asset Quality Index of 78.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of GBX1.80 Million minus total liabilities of GBX381.00K yields net assets of GBX1.42 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read debt load of CRISM Therapeutics Corporation for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
CRISM Therapeutics Corporation Net Asset Quality Index Over Time (2006–2025)
This chart shows how CRISM Therapeutics Corporation's Net Asset Quality Index has evolved across 20 annual periods from 2006 to 2025. As of December 2025, the index stands at 78.8%, representing net assets of GBX1.42 Million against total assets of GBX1.80 Million GBX. For live market cap and overall valuation, see CRISM Therapeutics Corporation stock valuation.
Annual Net Asset Quality Index for CRISM Therapeutics Corporation (2006–2025)
The table below presents the year-by-year Net Asset Quality Index for CRISM Therapeutics Corporation from 2006 to 2025, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See CRISM Therapeutics Corporation net assets for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (GBX) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 78.8% | GBX1.42 Million | GBX1.80 Million | GBX381.00K | ▼ -2.4 pp |
| 2024 | 81.2% | GBX1.48 Million | GBX1.82 Million | GBX341.00K | ▲ +554.5 pp |
| 2023 | -473.2% | GBX-759.66K | GBX160.53K | GBX920.19K | ▼ -570.0 pp |
| 2022 | 96.8% | GBX23.13 Million | GBX23.89 Million | GBX765.65K | ▲ +0.4 pp |
| 2021 | 96.4% | GBX30.11 Million | GBX31.24 Million | GBX1.13 Million | ▼ -0.4 pp |
| 2020 | 96.7% | GBX31.35 Million | GBX32.40 Million | GBX1.05 Million | ▲ +0.7 pp |
| 2019 | 96.0% | GBX20.48 Million | GBX21.34 Million | GBX852.24K | ▲ +6.5 pp |
| 2018 | 89.5% | GBX23.48 Million | GBX26.24 Million | GBX2.76 Million | ▼ -7.3 pp |
| 2017 | 96.8% | GBX28.20 Million | GBX29.14 Million | GBX944.00K | ▲ +9.9 pp |
| 2016 | 86.8% | GBX25.55 Million | GBX29.43 Million | GBX3.88 Million | ▼ -8.7 pp |
| 2015 | 95.5% | GBX15.21 Million | GBX15.91 Million | GBX709.20K | ▼ -2.5 pp |
| 2014 | 98.1% | GBX20.72 Million | GBX21.12 Million | GBX407.00K | ▼ -1.5 pp |
| 2013 | 99.6% | GBX18.05 Million | GBX18.13 Million | GBX74.25K | ▲ +0.0 pp |
| 2012 | 99.5% | GBX16.12 Million | GBX16.19 Million | GBX73.21K | ▲ +0.0 pp |
| 2011 | 99.5% | GBX21.19 Million | GBX21.29 Million | GBX102.00K | ▲ +0.0 pp |
| 2010 | 99.5% | GBX21.29 Million | GBX21.40 Million | GBX109.60K | ▲ +1.2 pp |
| 2009 | 98.3% | GBX16.52 Million | GBX16.81 Million | GBX289.43K | ▲ +0.9 pp |
| 2008 | 97.4% | GBX10.78 Million | GBX11.07 Million | GBX292.12K | ▼ 0.0 pp |
| 2007 | 97.4% | GBX6.53 Million | GBX6.71 Million | GBX175.32K | ▼ -2.4 pp |
| 2006 | 99.8% | GBX9.33 Million | GBX9.35 Million | GBX15.71K | — |